TriCelX Files IND and Seeks RMAT Designation for XytriX™ in Knee Osteoarthritis

TriCelX announced the submission of a Phase 1/2 Investigational New Drug (IND) application to the FDA for XytriX™, an allogeneic umbilical cord-derived mesenchymal stem cell (MSC) therapy targeting knee osteoarthritis. At the same time, the company requested Regenerative Medicine Advanced Therapy (RMAT) designation, a pathway designed to expedite development for promising therapies addressing serious conditions.

Learn more